AbbVie Updates 2026 EPS Guidance (ABBV)

AbbVie's October 5, 2026 guidance update formally incorporates Q3 IPR&D charges and milestone-related expenses into its 2026 EPS range. The company has signaled that acquisition-related intangible research and development (IPR&D) and contingent milestone costs are being reflected in reported guidance rather than being excluded from adjusted metrics. This aligns with the company’s prior communication on July 6, 2026, when AbbVie adjusted Q2 and full-year 2026 adjusted EPS guidance to account for acquired IPR&D and milestone expenses. The inclusion of these items in the 2026 EPS range is consistent with recent corporate activity: AbbVie completed the Apogee Therapeutics acquisition on September 3, 2026, and funded that deal in part via senior notes issued on August 5, 2026. Those transactions are the proximate drivers of the IPR&D and milestone charges now captured in the updated guidance.

For investors, the key takeaway is that AbbVie’s reported 2026 EPS will reflect acquisition-related investment in R&D assets and milestone obligations. That accounting treatment can compress reported EPS relative to adjusted measures that exclude such items, so investors should check both reported and adjusted EPS series when assessing near-term performance. The guidance update must be viewed in the context of AbbVie’s broader strategy and risk profile. Management remains focused on advancing a diversified portfolio across immunology, oncology, neuroscience, aesthetics and eye care while returning cash to shareholders and managing debt. Recent filings show substantial intangible assets and previous contingent consideration volatility (a $5.1 billion fair value change in 9M 2025), underscoring how acquisitions and milestone obligations can affect earnings volatility. Regulatory and market risks noted in filings—such as biosimilar competition, Medicare pricing impacts, and ongoing litigation—remain relevant to longer-term EPS trajectory.

Monitor upcoming quarterly results and the company’s reconciliations between reported and adjusted EPS to see the exact quantitative impact of the Q3 IPR&D and milestone items on 2026 earnings. Watch balance-sheet activity and debt schedules following the senior notes issuance that funded recent M&A, and follow pipeline milestones and regulatory readouts for assets cited by management (e.g., Skyrizi/Rinvoq expansions, oncology ADCs and bispecifics) that underpin growth beyond Humira-era dynamics. Given AbbVie's stated strategy—R&D investment, regulatory submissions, and M&A—investors should focus on how acquisition-related charges translate into future revenue and earnings contributions from newly acquired programs.